☆ 4.7 Editorial Material

Randomized trials in oncology stopped early for benefit

JOURNAL OF CLINICAL ONCOLOGY (2008)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 26, Issue 1, Pages 18-19

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2007.13.6259

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Health Care Sciences & Services

Estimation of the treatment effect following a clinical trial that stopped early for benefit

Ian C. Marschner, Manjula Schou, Andrew J. Martin

Summary: This paper addresses the issue of clinical trials stopping early for benefit and proposes a penalised maximum likelihood estimate as a supplementary analysis. The method shows good properties and efficiency when the trial is stopped early for benefit.

STATISTICAL METHODS IN MEDICAL RESEARCH (2022)

Add to Collection

Article Multidisciplinary Sciences

The effects of releasing early results from ongoing clinical trials

Steffen Ventz, Sergio Bacallado, Rifaquat Rahman, Sara Tolaney, Jonathan D. Schoenfeld, Brian M. Alexander, Lorenzo Trippa

Summary: The study highlights the importance of sharing early efficacy and toxicity results during ongoing clinical trials for physicians and patients to make informed enrollment decisions. This practice may impact various operating characteristics, trial duration, and statistical validity.

NATURE COMMUNICATIONS (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Common misconceptions of randomized controlled trials in oncology

Kerrington Powell, Vinay Prasad

Summary: Randomized controlled trials are highly valued in biomedicine for their ability to minimize confounding factors. However, there are misconceptions in oncology regarding the difficulty, time, cost, industry influence, and ethical standards of conducting these trials. Potential solutions include improving trial design, establishing regulatory and strategic frameworks, and addressing ethical concerns.

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2022)

Add to Collection

Letter Medicine, General & Internal

Reporting of Physicians' or Investigators' Choice of Treatment in Oncology Randomized Clinical Trials

Timothee Olivier, Alyson Haslam, Vinay Prasad

Summary: This cross-sectional study investigates the commonness of restricted choice of treatment among physicians and investigators conducting oncology randomized clinical trials (RCTs) in control groups.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Endocrinology & Metabolism

ENSAT registry-based randomized clinical trials for adrenocortical carcinoma

Joakim Crona, Eric Baudin, Massimo Terzolo, Alexandra Chrisoulidou, Anna Angelousi, Cristina L. Ronchi, Cristina Lamas Oliveira, Els J. M. Nieveen van Dijkum, Filippo Ceccato, Francoise Borson-Chazot, Giuseppe Reimondo, Guido A. M. Tiberi, Hester Ettaieb, Andreas Kiriakopoulos, Canu Letizia, Darko Kastelan, Esthr Osher, Eugenia Yiannakopoulou, Giorgio Arnaldi, Guillaume Assie, Isabel Paiva, Isabelle Bourdeau, John Newell-Price, Karolina M. Nowak, M. Tous Romero, Maria Cristina De Martino, Maria Joao Bugalho, Mark Sherlock, Marie-Christine Vantyghem, Michael Conall Dennedy, Paula Loli, Patrice Rodien, Richard Feelders, Ronald de Krijger, Sam Van Slycke, Simon Aylwin, Valentina Morelli, Laurent Vroonen, Zulfiya Shafigullina, Irina Bancos, Malgorzata Trofimiuk-Mueldner, Marcus Quinkler, Michaela Luconi, Matthias Kroiss, Mitsuhide Naruse, Peter Igaz, Radu Mihai, Silvia Della Casa, Alfredo Berruti, Martin Fassnacht, Felix Beuschlein

Summary: Adrenocortical carcinoma is a rare disease with limited treatment options. Registry-based clinical trials are seen as a cost-effective approach with high scientific potential. ENSAT is considering transforming their current registry into a clinical trial infrastructure to conduct randomized registry-based trials for ACC patients.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials

Domenico D'Amario, Renzo Laborante, Emiliano Bianchini, Mattia Galli, Giuseppe Ciliberti, Marco Mennuni, Giuseppe Patti

Summary: This study conducted a meta-analysis of randomized controlled trials (RCTs) to investigate the cardio-protective role of statins in cancer patients treated with anthracyclines. The results showed that statin-treated patients had a lower incidence of cardiotoxicity and higher mean LVEF compared to the placebo group. However, there was significant heterogeneity in the analysis of LVEF and Delta LVEF. More high-powered RCTs are needed to fully understand the impact of statins on prognosis in patients receiving anthracycline therapy.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2023)

Add to Collection

Article Computer Science, Artificial Intelligence

Early-stopped learning for action prediction in videos

Mehrin Saremi, Farzin Yaghmaee

Summary: This paper introduces a learning framework that enhances the applicability of deep learning methods in early action recognition. By encouraging learners to focus on the early parts of a video and identifying a stopping point for learning, the model can better utilize the information in these early parts.

INTERNATIONAL JOURNAL OF MULTIMEDIA INFORMATION RETRIEVAL (2021)

Add to Collection

Article Oncology

Optimal predictive probability designs for randomized biomarker-guided oncology trials

Emily C. Zabor, Alexander M. Kaizer, Nathan A. Pennell, Brian P. Hobbs

Summary: This study proposes three randomized designs for early phase biomarker-guided oncology clinical trials, using optimal efficiency predictive probability method to monitor multiple biomarker subpopulations for futility. The simulation study demonstrates that potentially smaller phase II trials can be designed efficiently using randomization and futility stopping to obtain more information before phase III studies.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Oncology

Translating Big Data in Oncology for Clinical Benefit: Progress or Paralysis

Anna D. Barker, Jerry S. H. Lee

Summary: The big data revolution in cancer research is leading to progress and challenges, requiring a rebuild of an information and evidence-based learning system.

CANCER RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials

Dai Chihara, Ruitao Lin, Christopher R. Flowers, Shanda R. Finnigan, Lisa M. Cordes, Yoko Fukuda, Erich P. Huang, Larry Rubinstein, Loretta J. Nastoupil, S. Percy Ivy, James H. Doroshow, Naoko Takebe

Summary: This study found that the response rate in phase 1 trials for solid tumors has nearly doubled in the past 20 years, without an increase in the treatment-related death rate. However, there is significant heterogeneity in overall response based on various factors such as cancer type, investigational agent, and trial design.

LANCET (2022)

Add to Collection

Review Health Care Sciences & Services

Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials

Hannah Moyer, Merlin Bittlinger, Angela Nelson, Luciano Fernandez, Jacky Sheng, Yuetong Wang, Joseph C. Del Paggio, Jonathan Kimmelman

Summary: The prevalence of P2 bypass in phase 3 trials was estimated in this study, and the safety and efficacy results were compared between trials that bypassed phase 2 and those that did not.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2023)

Add to Collection

Article Oncology

Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials

Lei Bian, Ping Yu, Jiahuai Wen, Na Li, Wanwei Huang, Xiaoming Xie, Feng Ye

Summary: Platinum-based chemotherapy regimens have been shown to significantly improve disease-free survival (DFS) and overall survival (OS) in early stage triple negative breast cancer (eTNBC) treatment. Whether adding platinum to standard anthracyclines & taxanes based regimens or combining platinum with taxanes alone, both strategies demonstrate consistent survival benefits in eTNBC patients. The present meta-analysis recommends platinum-based regimens, particularly the A&T + Pt mode, for eTNBC patients, if tolerable toxicities, to potentially revolutionize TNBC therapy.

NPJ BREAST CANCER (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

Alberto Cordero, Rosa Fernandez Olmo, Carlos Garcia Santos-Gallego, Lorenzo Facila, Clara Bonanad, Jose Maria Castellano, Moises Rodriguez-Manero, Jose Seijas-Amigo, Jose R. Gonzalez-Juanatey, Juan J. Badimon

Summary: Bempedoic acid is a selective inhibitor that reduces LDL cholesterol levels and has potential cardiovascular benefits. However, there is controversy regarding its net clinical benefit. This meta-analysis of four clinical trials provides reliable evidence that treatment with Bempedoic acid significantly reduces the incidence of major adverse cardiovascular events, myocardial infarction, and myocardial revascularization.

AMERICAN JOURNAL OF CARDIOLOGY (2023)

Add to Collection

Review Clinical Neurology

Robustness of Randomized Control Trials Supporting Current Neurosurgery Guidelines

N. U. Farrukh Hameed, Xiaoran Zhang, Omar Sajjad, Sam Sathyamurthi, Maadeha H. H. Zaidi, Nicolina Jovanovich, Ahmed Habib, Mamindla Priyadharshini, Pascal O. O. Zinn

Summary: This study evaluated the robustness of randomized controlled trials (RCTs) supporting the current guidelines for neurosurgical treatments. The results showed that the trials supporting neuro-oncological and neurovascular surgical interventions have low robustness.

NEUROSURGERY (2023)

Add to Collection

Article Oncology

If only I had, patients' experiences during early oncology trials

Maaike E. A. van Sasse van IJsselt, Diane A. J. van der Biessen, Andrea J. van Puffelen, Debbie G. J. Robbrecht, Wendy H. H. Oldenmenger

Summary: This study aims to explore the relationship between the self-determination theory and the motivations of participants in early clinical trials (ECT). Through qualitative interviews and thematic analysis, it was found that participants' motivations include competence, relatedness, and autonomy, and they have a positive motivation to continue participating in the trials.

SUPPORTIVE CARE IN CANCER (2023)

Add to Collection

Editorial Material Medicine, General & Internal

COVID-19 Testing: The Threat of False -Negative Results

Colin P. West, Victor M. Montori, Priya Sampathkumar

MAYO CLINIC PROCEEDINGS (2020)

Add to Collection

Letter Oncology

RE: I Think It's Been Met With a Shrug: Oncologists' Views Toward and Experiences With Right-to-Try Response

Zubin Master, Alex A. Adjei, Ian G. Hargraves, Victor M. Montori, Jon C. Tilburt

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Add to Collection

Article Medicine, General & Internal

An International, Mixed-Methods Study of the Perceived Intrusiveness of Remote Digital Diabetes Monitoring

Theodora Oikonomidi, Philippe Ravaud, Arthur James, Emmanuel Cosson, Victor Montori, Viet-Thi Tran

Summary: This study assessed the relationship between remote digital monitoring modalities for diabetes and intrusiveness in patients' lives. Results showed that food monitoring, real-time human feedback, and private-sector data handling were associated with increased intrusiveness. Additionally, practical/psychosocial burden, control, data safety/misuse, and dehumanization of care were identified as drivers of intrusiveness.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Endocrinology & Metabolism

Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities

Rozalina G. McCoy, Holly K. Van Houten, Pinar Karaca-Mandic, Joseph S. Ross, Victor M. Montori, Nilay D. Shah

Summary: The study found that patients with cardiovascular disease, heart failure, and nephropathy were less likely to initiate GLP-1RA and SGLT2i therapy, which have established benefits, compared to DPP-4i. Addressing this treatment/benefit paradox, especially in non-White and older patients, may help reduce morbidity associated with these conditions.

DIABETES CARE (2021)

Add to Collection

Editorial Material Health Care Sciences & Services

Removing the blindfold: The centrality of care in caring for patients with multiple chronic conditions

Victor M. Montori

HEALTH SERVICES RESEARCH (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Minimally Disruptive Medicine: Progress 10 Years Later

Kasey R. Boehmer, Katie Gallacher, Kate A. Lippiett, Frances S. Mair, Carl R. May, Victor M. Montori

MAYO CLINIC PROCEEDINGS (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Co-creating sensible care plans using shared decision making: Patients? reflections and observations of encounters

Marleen Kunneman, Ian G. Hargraves, Angela L. Sivly, Megan E. Branda, Christina M. LaVecchia, Nanon H. M. Labrie, Sarah Brand-McCarthy, Victor Montori

Summary: By analyzing the impact of the use of a within-encounter SDM tool on the sensibility of care plans for patients with atrial fibrillation, it was found that the sensibility of the plans was similar in both groups, and it was weakly correlated with decisional conflict but not with patient involvement or adherence. Most patients found their care plans sensible based on known efficacy, safety, and implementation factors.

PATIENT EDUCATION AND COUNSELING (2022)

Add to Collection

Article Health Care Sciences & Services

Problem-based shared decision making: The role of canonical SDM steps

Victor M. Montori, Merel M. Ruissen, Megan E. Branda, Ian G. Hargraves, Marleen Kunneman

Summary: This study aims to evaluate the implementation of shared decision making (SDM) in clinical encounters and across different SDM forms. The findings suggest that the prescribed steps of SDM are rarely followed in order, regardless of whether an SDM intervention was used. There is no clear pattern of steps that distinguishes among different SDM forms.

HEALTH EXPECTATIONS (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Caring without boundaries: delimiting shared decision-making

Victor Montori, Marleen Kunneman

BMJ EVIDENCE-BASED MEDICINE (2023)

Add to Collection

Editorial Material Medicine, General & Internal

Shared decision-making as a method of care

Victor M. Montori, Merel M. Ruissen, Ian G. Hargraves, Juan P. Brito, Marleen Kunneman

BMJ EVIDENCE-BASED MEDICINE (2023)

Add to Collection

Review Health Care Sciences & Services

Assessing collaborative efforts of making care fit for each patient: A systematic review

Marleen Kunneman, Derek Gravholt, Sandra A. Hartasanchez, Michael R. Gionfriddo, Zoe Paskins, Larry J. Prokop, Anne M. Stiggelbout, Victor M. Montori

Summary: This study aimed to summarize instruments capable of measuring dimensions of patient-clinician collaboration to make care fit. The researchers systematically searched several databases and included 189 relevant papers. The results showed that existing measures of making care fit focus heavily on the content and manner of patient-clinician collaboration, while neglecting other crucial dimensions and actions.

HEALTH EXPECTATIONS (2023)

Add to Collection

Letter Medicine, General & Internal

Applying the time needed to treat to NICE guidelines on lifestyle interventions

Loai Albarqouni, Victor Montori, Karsten Juhl Jorgensen, Martin Ringsten, Helen Bulbeck, Minna Johannson

BMJ EVIDENCE-BASED MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Problem-based shared decision-making in diabetes care: a secondary analysis of video-recorded encounters

Merel M. Ruissen, Victor M. Montori, Ian G. Hargraves, Megan E. Branda, Montserrat Leon Garcia, Eelco J. P. de Koning, Marleen Kunneman

Summary: This study aimed to describe the collaborative approaches to shared decision-making (SDM) in clinical encounters of patients with diabetes and their clinicians. The findings showed that at least one instance of SDM was observed in 86 out of 100 encounters, with varying forms of SDM present. Weighing alternatives, negotiating conflicting desires, and problemsolving were the most common forms of SDM observed. The study also found a correlation between the form of SDM focused on weighing alternatives and higher patient involvement. Overall, recognizing the different forms of SDM used by clinicians and patients opens new possibilities for research and practice in patient-centered care.

BMJ EVIDENCE-BASED MEDICINE (2023)

Add to Collection

Review Endocrinology & Metabolism

Statin intolerance management: a systematic review

Alejandra Meza-Contreras, Camila Wenczenovicz, Kim Ruiz-Arellanos, Elissa A. Kinzelman Vesely, Renzo Mogollon, Victor M. Montori

Summary: This systematic review examined 26 articles on expert recommendations for statin intolerance, revealing substantial variability in the definition and management approaches. Most experts provided management suggestions, but lacked supporting evidence. Few experts focused on reducing atherosclerotic cardiovascular disease (ASCVD) risk, and none promoted shared decision making with patients.

ENDOCRINE (2023)

Add to Collection

Article Endocrinology & Metabolism

The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes

Francisco J. Barrera, Freddy JK. Toloza, Oscar J. Ponce, Jorge A. Zuniga-Hernandez, Larry J. Prokop, Nilay D. Shah, Gordon Guyatt, Rene Rodriguez-Gutierrez, Victor M. Montori

Summary: The current randomized trial evidence does not show significant reductions in type 2 diabetes complications with tight glycemic control, but economic analyses suggest it is cost-effective. The reliance on observational studies linking glycemic control to diabetes-related complications, without incorporating systematic review estimates from randomized trials, may bias the cost-effectiveness estimates of interventions to improve glycemic control.

ENDOCRINE (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.